Johnson & Johnson is offloading its Ortho Diagnostics business for $4 billion. The company announced Monday that it accepted the Carlyle Group’s January offer to take on the business, which includes in-vitro diagnostic products.

Bloomberg reports that Carlyle expects to run the unit as a standalone business, and that the transaction relieves J&J of its only diagnostics division.